The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

T T Yee, A Griffioen, C A Sabin, G Dusheiko, C A Lee

Abstract

Aim—This study describes the long term follow up of haemophilic patients infected with hepatitis C virus (HCV) between 1961 and 1985.

Methods—Clinical and treatment records from 310 patients with inherited coagulation disorders treated with blood product before 1985 were reviewed. Standard survival analysis methods were used to model progression to liver failure and death.

Results—A total of 298/305 (98%) patients tested were anti-HCV positive. Twenty seven (9%) individuals consistently HCV seroconverted to HCV positive. Twenty six (8%) had died a liver related death, and 61 (20%) had died from other, predominately human immunodeficiency virus (HIV) related, causes. Kaplan-Meier progression rates to death from any cause and liver related deaths 25 years after exposure to HCV were 47% (95% confidence intervals (CI) 34-60) and 19% (95% CI 10-27), respectively. After 13.3 years from 1985, by which time all patients had seroconverted to HIV, progression rates to death from any cause and liver related deaths were, respectively, 8% (95% CI 4-13) and 3% (95% CI 0.4-6) for those HIV negative, and 57% (95% CI 48-66) and 21% (95% CI 13-31) for those HIV positive (p=0.0001). Using Cox proportional hazard models, the adjusted relative hazard of death for individuals coinfected with HIV compared with those infected with HCV alone was 19.47 (95% CI 9.22-41.10), 0.99 (95% CI 0.39-2.53), 3.47 (95% CI 1.40-8.63), and 9.74 (95% CI 3.91-24.26) for the age groups at infection 10-19 years, 20-29 years, and 30+ years, respectively, compared with the age group <10 years. The adjusted relative hazard for genotype 1 compared with other genotypes was 2.7 (95% CI 1.36-5.15).

Conclusions—While 25 year follow up of 310 haemophilic patients has shown the potentially lethal combination of HIV and HCV coinfecion, HCV singly infected individuals show slow progression of liver disease.

(Gut 2000;47:845-851)

Keywords: hepatitis C virus; human immunodeficiency virus; haemophilia

A recent WHO report has underlined the importance of hepatitis C virus (HCV) as an emerging disease in public health programmes because of the significant morbidity and mortality caused in most parts of the world. Therefore, observation of long term infection is intrinsic to the successful management of an estimated 170 million individuals who are infected with HCV worldwide.

It is now firmly established that there is an emerging risk of morbidity and mortality from liver disease and primary liver cancer due to HCV among haemophilic patients in the UK. We have been monitoring a subpopulation of these patients, a total of 310 individuals with inherited bleeding disorders who were infected with HCV, from the time of first exposure to blood products. In almost all cases, first exposure was the date of infection of HCV before the introduction of virucidal treatment in 1985.

We last reported on this cohort in 1993, and we have extended our observation of the natural history of this infection to 1999. This represents two decades of HCV infection for most patients. We have included detailed individual patient observations, including date of infection, HCV viral load, and genotype, as well as cause of death and influence of treatment. Although the natural history of HCV infection is different in some respects in this patient population compared with other risk groups, the study has the advantage of the knowledge of duration of infection and of long term follow up at a single centre in London, UK.

Methods

FOLLOW UP

The Royal Free Hospital Haemophilia Centre was established in 1964 and therefore it was possible to review the clinical and treatment records of all patients from this time until 1 September 1999. A computerised database was introduced in 1980. Over this period, patients with severe haemophilia (factor <2 U/dl) were seen six monthly and those with other inherited clotting deficiencies annually. From 1985 onwards, human immunodeficiency virus (HIV) seropositive patients were seen at least three monthly. Assessment included medical history, review of home and inpatient treatment records, physical examina-

Abbreviations used in this paper: HCC, hepatocellular carcinoma.

HCV, hepatitis C virus; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma.
Willebrand's disorder were treated with cryoprecipitate or desmopressin before 1985. Patients with factor XI deficiency were treated with fresh frozen plasma until a heated large pool clotting factor concentrate became available in 1990. A total of 76 patients received antiviral therapy for HCV in 106 treatment episodes. Two patients received alpha interferon alone in 53 treatment episodes, including five patients who were treated twice and one who received three courses of therapy. We participated in a double blind controlled trial of ribavirin versus placebo in 12 patients in 1990, and subsequently continued open label therapy in two individuals. Combination therapy with ribavirin and alpha interferon was commenced in 1996: of a total of 37 HIV negative patients treated, 33 have completed the course.

Statistical methods
Comparisons between groups were made using the chi-square test or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous variables because of the expected non-normality of these variables. Standard survival analysis methods were used to model progression to death. Person-years at risk were calculated using the date of first exposure to unsterilised concentrate until death or 1 September 1996. For those patients lost to follow up (49 (16%)), the end point was taken as the date when the patient was last reviewed at the centre; information on last attendance at another centre was used where available. Kaplan-Meier progression rates and 95% confidence intervals (CI) were calculated from 1985 until the censoring date for analyses relating to HIV infection. To visually illustrate the impact of HIV infection on survival, Kaplan-Meier plots were also drawn using a baseline date of 12 January 1985 by which time 22 patients who became HIV positive patients had seroconverted. Cox proportional hazard models were used to compare survival between groups. HCV genotype and age at first exposure to concentrations were used to group patients: <10 years, 10–19 years, 20–29 years, and ≥30 years of age were taken as fixed covariates at baseline. Seroconversion to HIV and time of first anti-HIV therapy were considered as time updated covariates, taking the value 0 prior to the time of seroconversion/ starting therapy and 1 thereafter. The first exposure date was known for 228 (74%) patients. For those patients for whom the exposure date was not known, the median exposure date, July 1977, was used. Analyses were repeated, including only those individuals with a known date of infection. Results of these analyses were unchanged and therefore not included.

Virology and Immunology

Fresh or serum stored from 1979 from patients who had received any blood product were tested for antibodies to HCV using a second generation enzyme immunoassay EIA (Ortho Diagnostics, Amersham, UK). RIBA-2 was used as a confirmatory test in those who appeared to have cleared HCV infection naturally and were polymerase chain reaction (PCR) negative. Confirmation of ongoing HCV infection was made by detection of HCV viraemia either by qualitative reverse transcriptase PCR (AmpliVet HCV Test, Roche, Lewes, UK) or branched DNA (bDNA) assays. HCV genotyping was performed by extracting serum RNA from which HCV RNA was detected by reverse transcription and nested PCR using primers derived from the 5' non-coding region of the HCV genome. Genotype was determined from the pattern of DNA fragmentation after digestion of the PCR product with the two enzyme pairs Mva 1 + Hin1 and Hae III+Rsa I. Hepatitis B surface antigen (HBsAg) was tested by EIA (Murex Diagnostics, Abbott, Maidenhead, UK). Antibodies to HIV were tested by EIA (Wellcozyme, Murex Diagnostics, Abbott, Maidenhead, UK) and confirmed by gelatin particle agglutination (Mast Diagnostics, Liverpool, UK) and Abbott, Maidenhead, UK).

Results

Serological and viral testing for HCV
Of the 310 patients who had been treated with non-virocidally treated blood products, 305 were tested for HCV and five patients who had also been treated with large pool non-virocidally treated clotting factor concentrate) had died before HCV antibody tests became available and there were no stored serum samples available for testing. A total of 298/305 (98%) patients were anti-HCV positive and the remaining seven (2%) were anti-HCV negative. Of the 200 patients in whom it was possible to determine HCV viraemia, 27/200 (14%) were consistently HCV PCR negative in recent and archived specimens. These 27 individuals were thought to have cleared the virus and were studied in more detail.

Exposure to HCV and HIV
Of the 310 patients who were exposed to a high HCV risk blood product, the source of infection was thought to be large pool non-virocidally treated concentrate in 287 (93%), and of these the date of exposure was known in 216 (75%); median date was July 1977 (range 1961–1985). One patient was treated with factor IX concentrate as early as May 1961 in Oxford. Of the 22 patients who became infected after cryoprecipitate, the date of infection was known in 11, including one patient who was a carrier of haemophilia A and developed fulminant hepatitis C following...
HCV in a haemophilic cohort

A patient who was treated with several hundred donor units of cryoprecipitate in 1981, a patient who was treated with several hundred donor units of cryoprecipitate in another hospital in 1990 was the only patient infected after 1985. Six patients, of whom two had died, were HBsAg positive. Previous study of this cohort of patients using archival specimens showed that patients were infected with HCV between 1979 and 1985 (median seroconversion date 1983).

DEMOGRAPHICS (TABLE 1)
Of the total 310 patients, 223 (72%) were alive on 1 September 1999, 26 (8%) had died of liver related diseases, and 61 (20%) had died from other causes. The inherited coagulation disorders were haemophilia A, factor VIII deficiency (227 (73%)); haemophilia B, factor IX deficiency (49 (16%)); von Willebrand's disease (25 (8%)); and other deficiencies (nine (3%)). This distribution reflects the relative prevalence of these disorders in the haemophilic population. There were a higher number of deaths within the haemophilia A group (85% of 26 liver related deaths and 95% of 61 deaths not caused by liver disease). Of the total 87 deaths, 80 patients had haemophilia A, five haemophilia B, and two von Willebrand's disease. Of the total population of 310, 125 (40%) were infected with HIV and of these 54 were alive, 20 had died from a liver associated disease, and 51 had died of other predominantly HCV related causes. HCV genotyping was performed in 213/310 (69%) patients: 135 (63%) were type 1, 29 (14%) type 2, 39 (18%) type 3, and 10 (5%) other genotypes. Of the 28 (8%) living patients who were tested for HCV viraemia, 113 (70%) were positive. Of the 57 patients who were PCR negative for HCV, 27 (9%) were thought to have cleared the virus. All seven individuals who died of liver related diseases were HCV RNA positive. The HCV viral load in serum was higher in patients who had died from liver related disorders (median 19.1x10^5 compared with 8.1x10^5 genome eq/ml in those still alive (p=0.16).

KAPLAN-MEIER ANALYSES
Progression rates to death from any cause and deaths related to liver disease 25 years after exposure to HCV were 47% (95% CI 34-60) and 19% (95% CI 10-27), respectively (fig 1). Patients were infected with HCV during the years 1979–1985, by which time virucidal treatment of large pool clotting factor concentrates was in use. Therefore, in order to show the effect of HIV on the progression of HCV related liver disease, Kaplan-Meier analyses were calculated from 1985, by which time all patients would have seroconverted to HCV. Thus over a 13.3 year interval from 1985, progression to death related to liver disease, yearly progression rates to death related to liver disease was 3% (95% CI 0.4-6) and 21% (95% CI 13-31) for those HIV negative and positive, respectively (p=0.0001; fig 2A); progression to death related to liver disease was 3% (95% CI 0.4-6) and 21% (95% CI 13-31) for those HIV negative and positive, respectively (p=0.0001; fig 2B).

COX PROPORTIONAL HAZARDS MODELS
The influence of HCV genotype, HIV coinfection, age at infection, and time of first anti-HCV therapy were examined using Cox
was 19.47 (95% CI 9.22-41.10) after adjusting for age and genotype, for those infected with HCV alone was 17.51 (95% CI 5.82-52.72). The adjusted relative hazard for genotype 1 compared with other genotypes was 2.65 (95% CI 1.36-5.15).

The relative hazard of liver related death, adjusted for age and genotype, for those infected with HIV compared with those infected with HCV alone was 17.51 (95% CI 5.82-52.72). The adjusted relative hazard for genotype 1 compared with other genotypes was 7.78 (95% CI 1.96-30.85). After adjusting for genotype and HIV infection, the relative hazards of liver related death were 1.66 (95% CI 0.17-16.12), 16.04 (95% CI 1.06-131.45), and 45.93 (95% CI 5.47-385.91) for the age groups at infection 10-19 years, 20-29 years, and >30 years, respectively, compared with the age group <10 years. This clearly shows that the relative hazard associated with progression to death increases with age at exposure to HCV. Thus coinfection with HCV, age at infection, and genotype 1 HCV were the major determinants of death. (As only six of the total 310 population were HBsAg positive, this was not taken into account in the hazards analysis.)

**Table 2**

<table>
<thead>
<tr>
<th>Variable</th>
<th>All deaths</th>
<th>Liver related deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Relative hazard</td>
<td>95% GI</td>
</tr>
<tr>
<td>(a) Unadjusted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype 1</td>
<td>1.91 (1.03-3.57)</td>
<td>0.04</td>
</tr>
<tr>
<td>HIV seroconversion*</td>
<td>7.60 (4.63-12.17)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Age (y) at HCV infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td>2.08 (0.96-4.31)</td>
<td>0.06</td>
</tr>
<tr>
<td>20-29</td>
<td>2.80 (1.25-6.29)</td>
<td>0.02</td>
</tr>
<tr>
<td>&gt;30</td>
<td>6.13 (3.11-13.30)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Time of first anti-HCV therapy*</td>
<td>0.71 (0.32-1.58)</td>
<td>0.41</td>
</tr>
<tr>
<td>(b) Adjusted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV seroconversion*</td>
<td>19.47 (9.22-41.10)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Age (y) at HCV infection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;10</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>10-19</td>
<td>0.99 (0.39-2.23)</td>
<td>0.987</td>
</tr>
<tr>
<td>20-29</td>
<td>1.47 (1.09-6.03)</td>
<td>0.087</td>
</tr>
<tr>
<td>&gt;30</td>
<td>0.74 (0.51-1.30)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Genotype 1</td>
<td>2.65 (1.50-5.35)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

*Time dependent variable.
HCV in a haemophilic cohort

NATURAL IMMUNITY
Of the 27 patients who were thought to have cleared the virus, 26 were male and one was female. Seven had severe haemophilia A (factor VIII <2 U/dl), seven had moderate/mild haemophilia A (factor VIII >2 U/dl), four severe haemophilia B (factor IX <2 U/dl), four mild/moderate haemophilia B (factor IX >2 U/dl), one was a carrier of haemophilia A, and four had von Willebrand's disease. Three (all with severe haemophilia A) of the 27 patients were coinfected with HIV. Three patients had been treated only with cryoprecipitate. The remaining 24 had been treated with both cryoprecipitate and large pool clotting factor concentrate of both US and UK donor pool origin. Age at first exposure was median 9 years (range 3 months to 56 years). In 25 patients, normal liver serum aminotransferases were recorded at least once a year for a median follow up period of 15 years. One of two patients who recorded abnormal liver aminotransferases had increased alcohol intake; the other received antiretroviral therapy for HIV and this was thought to be the cause of the abnormalities. Serial measurements of HCV viraemia were performed on a median of 5 (range 3–10) archived and recent (within the previous eight months) serum samples in these 27 patients. HCV RNA was undetectable in all 154 serum samples tested.

EFFECT OF TREATMENT
In total, 15/76 (20%) patients became HCV RNA negative by PCR following treatment. Anti-HCV therapy was not shown to influence progression to all or liver related deaths (table 2).

Discussion
This detailed follow up of 310 haemophilic patients has shown the lethal combination of HCV and HIV coinfection, with 47% progression to death from any cause and 19% to liver related death after 25 years. However, for those HCV positive individuals without HIV infection, we have shown that hepatitis C is a very slowly progressive disorder with a 3% progression rate to a liver related death from the time of HCV infection in 1985.

Severe liver disease has been reported in non-haemophilic immunosuppressed patients infected with HCV who are receiving corticosteroids and other immunosuppressive agents. This is unexplained but could be related to a cytotoxic effect of HCV. A similar adverse effect on the natural progression of HCV would be expected in patients with HIV infection, and this has previously been shown in homosexual and haemophilic patients, and intravenous drug users. HCV viral loads have been reported to be higher in coinfected individuals in previous studies in this cohort and by others. The viral load or level of circulating HCV RNA in serum is a reflection of both the rate of viral replication and the rate of virus clearance in the infected host. HCV, an RNA virus, has a high mutation rate which leads to generation of quasispecies. In untreated patients with chronic HCV infection the viral load is relatively stable. Viral loads found in our patients were relatively high, particularly in those coinfected with HIV, and presumably this reflects the inability to contain the virus in the face of immunosuppression.

We found that HCV genotype 1 was associated with an increased relative hazard of progressing to death from any cause and specifically to death from liver disease, even when this was adjusted for HIV infection and age at infection. Contradictory results have been reported with respect to the influence of genotype on progression. Genotype 1 was associated with more severe disease in 4176 HCV positive Japanese patients, and in a further Japanese study in 140 patients, genotype 1 was associated with deterioration of liver biopsy. Dusheiko et al also found more severe disease in type 1 compared with type 2 HCV infection. However, a recent study from Italy showed no role for genotype in determining disease outcome. We and others have also demonstrated the influence of genotype 1 HCV on HIV.

The large pool clotting factor used to treat these patients was obtained from donors in the UK and USA and thus the distribution of genotypes reflects the prevalent genotypes found in North Europe and North America (genotypes 1, 2, and 3). However, in haemophilic patients in the USA, 45%, 7%, and 42% are reported to have genotypes 1, 2, and 3 compared with 63%, 11%, and 18%, respectively in our cohort. The majority of these patients were exposed to many batches of clotting factor concentrate over a long period, each bottle being made from a donor pool of several thousand donors. It is not clear why a particular genotype becomes the dominant genotype in any one haemophilic patient. The prevalence of genotype 1 may reflect a less robust immune response at the time of infection with HCV, and this in turn could explain the influence of genotype 1 in hastening the progression of both HCV and HIV disease. Genotype 1 may have greater replication competence or may have been epidemiologically more prevalent prior to HIV infection.

We have shown that 9% of these haemophilic patients spontaneously cleared HCV, as have others, and almost half of individuals infected with anti-D immunoglobulin. The majority of patients who cleared HCV had non-severe haemophilia and therefore infrequent treatment with clotting factor concentrate. Thus viral variants, including more virulent variants, to which they will have been exposed is likely to have been less. Patients who cleared the virus were young at first exposure and therefore it is possible that their immune response at the time of infection was more effective. Thus a report from Germany showed that many individuals who had acquired hepatitis C infection in childhood during cardiac surgery had spontaneously cleared the virus after 20 years. Of patients who became infected with HIV from clotting factor concentrate, most would also have been infected with HCV, either at the same time or earlier. Thus it is remarkable that three individuals coinfected with HIV appar-
enately cleared HCV with consistently negative HCV viremia.

Two thirds of HIV negative patients who died in this study had increased alcohol consumption. Chronic alcoholism in patients with HCV appears to cause more severe and rapidly progressive liver disease, leading more frequently to cirrhosis of the liver and HCC.26

Excessive alcohol intake has been associated with increased HCV RNA levels as well as amino transferring levels, although the mechanism is poorly understood.27-30

HCV infection is now recognised as a major risk factor for HCC and there seems to be an incubation period of two or three decades on average.29 The four patients who died with HCV had been infected for two decades and this is likely to become more common in this group of patients who were infected from 1977 (median year).

One patient died only eight years after infection with HCV as a result of surgical bleeding after liver biopsy.31 It is largely as a result of this unfortunate experience that after an initial enthusiasm for liver biopsy32 we have chosen to manage this patient group conservatively relying on detailed clinical history, liver function tests, HCV genotype, viral load, and PCR, together with endoscopy and imaging to chart the natural history and monitor treatment for HCV. Thus data on cirrhosis are limited and include those for whom there was a rare biopsy performed in life or postmortem liver biopsy.

Clearly the challenge is to provide treatment to delay progression or "cure": these patients. Unfortunately, a large number have poor prognostic factors for successful eradication: male sex, high viral load, long period of infection, type 1 HCV, and HCV infection. Nevertheless, a minority of these patients responded to alpha interferon alone or combination therapy33 with response rates similar to those recently reported.12,22,34

We thank Dr Vince Emery, Department of Virology and Dr Helen Devonshire, Department of Biochemistry, Royal Free and University College Medical School, who gave helpful advice, the Department of Virology who performed the laboratory tests, and Ms Marie Johnson who prepared the manuscript. This work was undertaken by the Royal Free London NHS Trust who received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive; Dr Upton, Thorpe House is supported by the MRC, Anna Gronoff is supported by the Katharine Dormandy Trust, registered charity No 262 434.


The UEGW abstract book (Gut 2000;47(suppl III)) has again been produced as a CD-ROM and can be found attached to the inside back cover of this issue.
The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

T T Yee, A Griffioen, C A Sabin, et al.

Gut 2000 47: 845-851
doi: 10.1136/gut.47.6.845

Updated information and services can be found at:
http://gut.bmj.com/content/47/6/845.full.html

These include:

References
This article cites 37 articles, 5 of which can be accessed free at:
http://gut.bmj.com/content/47/6/845.full.html#related-urls

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/